Table 5.
ALL (n = 1176) | BCT (n = 948) | PMRT (n = 228) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Parameter | Level | n (%) | Incidence of BOOP syndrome, n (%) | p | n (%) | Incidence of BOOP syndrome, n (%) | p | n (%) | Incidence of BOOP syndrome, n (%) | p |
Age | <52y* | 559 (48) | 3 (0.5) | 0.023 | 457 (48) | 2 (0.4) | 0.039 | 102 (45) | 1 (1.0) | 0.63 |
>-52y | 617 (52) | 13 (2.1) | 491 (52) | 10 (2.0) | 126 (55) | 3 (2.4) | ||||
OneSide | One side | 1157 (98) | 16 (1.4) | 1.00 | 929 (98) | 12 (1.3) | 1.00 | 228 (100) | 4 (1.8) | - |
Bilateral | 19 (2) | 0 (0.0) | 19 (2) | 0 (0.0) | 0 (0) | 0 (0) | ||||
Allergy | Yes | 400 (34) | 6 (1.5) | 0.79 | 328 (35) | 5 (1.5) | 0.76 | 72 (32) | 1 (1.4) | 1.00 |
No | 775 (66) | 10 (1.3) | 619 (65) | 7 (1.1) | 156 (68) | 3 (1.9) | ||||
Unkonwn | 1 (0) | 0 (0.0) | 1 (0) | 0 (0.0) | 0 (0) | 0 (0.0) | ||||
Smoking | Yes | 201 (17) | 5 (2.5) | 0.17 | 147 (16) | 4 (2.7) | 0.10 | 54 (24) | 1 (1.9) | 1.00 |
No | 973 (83) | 11 (1.1) | 800 (84) | 8 (1.0) | 173 (76) | 3 (1.7) | ||||
Unkonwn | 2 (0) | 0 (0.0) | 1 (0) | 0 (0.0) | 1 (0) | 0 (0.0) | ||||
Chemotherapy | Yes | 607 (52) | 6 (1.0) | 0.32 | 389 (41) | 2 (0.5) | 0.14 | 218 (96) | 4 (1.8) | 1.00 |
No | 569 (48) | 10 (1.8) | 559 (59) | 10 (1.8) | 10 (4) | 0 (0.0) | ||||
ET | Yes | 796 (68) | 13 (1.6) | 0.29 | 635 (67) | 11 (1.7) | 0.12 | 161 (71) | 2 (1.2) | 0.58 |
No | 380 (32) | 3 (0.8) | 313 (33) | 1 (0.3) | 67 (29) | 2 (3.0) | ||||
RT | Yes | 765 (96) | 13 (1.7) | 1.00 | 614 (97) | 11 (1.8) | 1.00 | 151 (94) | 2 (1.3) | 1.00 |
No | 31 (4) | 0 (0.0) | 21 (3) | 0 (0.0) | 10 (6) | 0 (0.0) | ||||
Trastuzumab | Yes | 68 (6) | 2 (2.9) | 0.24 | 35 (4) | 0 (0.0) | 1.00 | 33 (14) | 2 (6.1) | 0.10 |
No | 1108 (94) | 14 (1.3) | 913 (96) | 12 (1.3) | 195 (86) | 2 (1.0) | ||||
Treatment | BCT | 948 (81) | 12 (1.3) | 0.53 | - | - | - | - | - | - |
PMRT | 228 (19) | 4 (1.8) | ||||||||
Boost | Yes | 963 (82) | 13 (1.3) | 1.00 | 902 (95) | 12 (1.3) | 1.00 | 61 (27) | 1 (1.6) | 1.00 |
No | 213 (18) | 3 (1.4) | 46 (5) | 0 (0.0) | 167 (73) | 3 (1.8) | ||||
Irradiation to the regional LNs | Yes | 269 (23) | 4 (1.5) | 0.77 | 58 (6) | 0 (0.0) | 1.00 | 211 (93) | 4 (1.9) | 1.00 |
No | 907 (77) | 12 (1.3) | 890 (94) | 12 (1.3) | 17 (7) | 0 (0.0) | ||||
Lung V20 | 0-4.9% | 280 (24) | 2 (0.7) | 0.19 | 274 (29) | 2 (0.7) | 0.62 | 6 (3) | 0 (0.0) | 0.32 |
5.0-9.9% | 620 (53) | 10 (1.6) | 586 (62) | 10 (1.7) | 34 (15) | 0 (0.0) | ||||
10.0-14.9% | 166 (14) | 1 (0.6) | 62 (7) | 0 (0.0) | 104 (46) | 1 (1.0) | ||||
15.0-19.9% | 93 (8) | 2 (2.2) | 22 (2) | 0 (0.0) | 71 (31) | 2 (2.8) | ||||
20.0-24.9% | 14 (1) | 1 (7.1) | 2 (0) | 0 (0.0) | 12 (5) | 1 (8.3) | ||||
25.0-29.9% | 0 (0) | 0 (0.0) | 0 (0) | 0 (0.0) | 0 (0) | 0 (0.0) | ||||
30.0-34.9% | 1 (0) | 0 (0.0) | 1 (0) | 0 (0.0) | 0 (0) | 0 (0.0) | ||||
Unkonwn | 2 (0) | 0 (0.0) | 1 (0) | 0 (0.0) | 1 (0) | 0 (0.0) |
P: by Fisher’s exact test.
*: median of age.
Abbreviations
BOOP Bronchiolitis obliterans organizing pneumonia.
ET Endocrine therapy.
RT Radiation therapy.
LNs Lymph nodes.
BCT Breast conserving therapy.
PMRT Postmastectomy radiation therapy.